Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.

MLA

Gerhardt, Kristin, et al. “Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.” Frontiers in Oncology, vol. 11, Sept. 2021, p. 737645. EBSCOhost, https://doi.org/10.3389/fonc.2021.737645.

APA

Gerhardt, K., Jentzsch, M., Georgi, T., Sretenović, A., Cross, M., Bach, E., Monecke, A., Leiblein, S., Hoffmann, S., Todorović, M., Bila, J., Sabri, O., Schwind, S., Franke, G.-N., Platzbecker, U., & Vučinić, V. (2021). Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases. Frontiers in Oncology, 11, 737645. https://doi.org/10.3389/fonc.2021.737645

Chicago

Gerhardt, Kristin, Madlen Jentzsch, Thomas Georgi, Aleksandra Sretenović, Michael Cross, Enrica Bach, Astrid Monecke, et al. 2021. “Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.” Frontiers in Oncology 11 (September): 737645. doi:10.3389/fonc.2021.737645.